AbbVie ROA 2010-2018 | ABBV

Current and historical return on assets (ROA) values for AbbVie (ABBV) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. AbbVie ROA for the three months ending September 30, 2018 was 17.63%.
AbbVie ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-09-30 $7.57B $66.16B 11.29%
2018-06-30 $6.45B $61.64B 9.53%
2018-03-31 $6.38B $69.34B 9.25%
2017-12-31 $5.31B $70.79B 7.80%
2017-09-30 $6.65B $68.84B 9.94%
2017-06-30 $6.62B $66.99B 9.97%
2017-03-31 $6.31B $65.66B 9.50%
2016-12-31 $5.95B $66.10B 9.39%
2016-09-30 $6.08B $66.63B 10.11%
2016-06-30 $5.72B $67.21B 10.00%
2016-03-31 $5.48B $53.72B 10.17%
2015-12-31 $5.14B $53.05B 10.92%
2015-09-30 $2.82B $54.83B 6.92%
2015-06-30 $2.08B $53.86B 6.11%
2015-03-31 $1.82B $26.70B 6.50%
2014-12-31 $1.77B $27.51B 6.24%
2014-09-30 $3.71B $28.45B 12.87%
2014-06-30 $4.17B $29.05B 14.49%
2014-03-31 $4.14B $28.66B 14.52%
2013-12-31 $4.13B $29.20B 14.67%
2013-09-30 $4.54B $28.25B 16.46%
2013-06-30 $5.16B $27.91B 19.70%
2013-03-31 $5.36B $27.17B 22.66%
2012-12-31 $5.28B $27.01B 24.42%
2012-09-30 $4.89B $22.73B 24.79%
2012-06-30 $3.32B $17.71B 23.63%
2012-03-31 $3.59B $18.96B 37.35%
2011-12-31 $3.43B $19.52B 70.34%
2011-09-30 $2.28B $0.00B 43.08%
2011-06-30 $2.26B $0.00B 42.83%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $134.597B $28.216B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $396.345B 18.58
Pfizer (PFE) United States $262.998B 14.83
Merck (MRK) United States $205.854B 17.84
Novartis AG (NVS) Switzerland $204.655B 17.49
Eli Lilly (LLY) United States $122.680B 21.57
Sanofi (SNY) France $112.713B 13.96
Novo Nordisk (NVO) Denmark $111.107B 18.04
AstraZeneca (AZN) United Kingdom $103.342B 12.83
GlaxoSmithKline (GSK) United Kingdom $101.256B 13.61
Bristol-Myers Squibb (BMY) United States $87.290B 14.38